<p>Maxim Group 的分析师 Jason McCarthy 对 OS Therapies Incorporated 维持买入评级，目标价为 6.00 美元。</p>
<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Jason McCarthy 给予买入评级的原因是多种因素的结合，突显了 OS Therapies Incorporated 的良好前景。最近与 FDA 的 C 类会议非常积极，支持基于他们在骨肉瘤单臂研究中的生存数据的加速批准潜力。此次会议确认，现有数据结合即将发布的生物标志物数据，可能为加速审批路径下的生物制品许可申请铺平道路。</p>
<p>此外，针对 HER2 表达癌细胞的 OST-HER2 项目，获得了 FDA 的多项认证，如孤儿药、快速通道和罕见儿科疾病，增强了其获得优先审查凭证的潜力。公司计划在即将召开的 JPM Healthcare Conference 上发布生物标志物数据，为申请提供战略支持。此外，FDA 对确认研究的指导，可能将适应症扩展到其他骨肉瘤领域，与公司的监管策略高度一致，进一步支持了 McCarthy 的乐观展望。</p>
<p>在今天发布的另一份报告中，Lake Street 也维持了该股票的买入评级，目标价为 17.00 美元。</p>

OSTX

<p>分析师 Jason McCarthy 来自 Maxim Group，对 OS Therapies Incorporated 维持买入评级，目标价为 6.00 美元。与 FDA 的积极 C 类会议支持了其骨肉瘤治疗的潜在加速批准。OST-HER2 项目拥有多个 FDA 认证，增强了其审查潜力。公司计划在 JPM 医疗会议上发布生物标志物数据。Lake Street 也维持买入评级，目标价为 17.00 美元</p>

<p>Analyst Jason McCarthy of Maxim Group maintained a Buy rating on OS Therapies Incorporated, retaining the price target of $6.00.</p>
<div class="lb-trans"><p>Maxim Group 的分析师 Jason McCarthy 对 OS Therapies Incorporated 维持买入评级，目标价为 6.00 美元。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Jason McCarthy has given his Buy rating due to a combination of factors that highlight the promising outlook for OS Therapies Incorporated. The recent Type C meeting with the FDA was notably positive, supporting the potential for accelerated approval based on the survival data from their single-arm study in osteosarcoma. This meeting confirmed that the existing data, when combined with upcoming biomarker data, could pave the way for a Biologics License Application under the Accelerated Approval Pathway.</p>
<div class="lb-trans"><p>Jason McCarthy 给予买入评级的原因是多种因素的结合，突显了 OS Therapies Incorporated 的良好前景。最近与 FDA 的 C 类会议非常积极，支持基于他们在骨肉瘤单臂研究中的生存数据的加速批准潜力。此次会议确认，现有数据结合即将发布的生物标志物数据，可能为加速审批路径下的生物制品许可申请铺平道路。</p>
</div><p>Furthermore, the OST-HER2 program, which targets HER2-expressing cancer cells, holds multiple FDA designations such as Orphan, Fast Track, and Rare Pediatric Disease, enhancing its potential for a priority review voucher. The company’s plan to release biomarker data at the upcoming JPM Healthcare Conference positions them strategically for filing. Additionally, the FDA’s guidance on a confirmatory study, which could expand the label to other osteosarcoma settings, aligns well with the company’s regulatory strategy, further supporting McCarthy’s optimistic outlook.</p>
<div class="lb-trans"><p>此外，针对 HER2 表达癌细胞的 OST-HER2 项目，获得了 FDA 的多项认证，如孤儿药、快速通道和罕见儿科疾病，增强了其获得优先审查凭证的潜力。公司计划在即将召开的 JPM Healthcare Conference 上发布生物标志物数据，为申请提供战略支持。此外，FDA 对确认研究的指导，可能将适应症扩展到其他骨肉瘤领域，与公司的监管策略高度一致，进一步支持了 McCarthy 的乐观展望。</p>
</div><p>In another report released today, Lake Street also maintained a Buy rating on the stock with a $17.00 price target.</p>
<div class="lb-trans"><p>在今天发布的另一份报告中，Lake Street 也维持了该股票的买入评级，目标价为 17.00 美元。</p>
</div>

OS Therapies 的前景乐观：买入评级受到积极的 FDA 会议和战略定位的支持